Global Hemophilia Drugs Market 2016-2020

Increasing focus on prophylactic treatment is a key driver for the global hemophilia drugs market

Extensive research carried out by the analysts at Technavio has shown that the global hemophilia drugs market will witness steady growth and will post a moderate CAGR of more than 5% over the forecast period. With an increasing focus on prophylactic treatment, the market for hemophilia drugs is expected to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline.

According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth.

Hemophilia drugs market based on geography

According to the hemophilia market overview, the Americas led the global hemophilia drugs market in 2015 and is expected to continue its dominance until the end of 2020. The Americas have the highest revenue share in the global market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on health care insurance and also reduce hospital stay and overall medical expenses, which will boost this market’s growth in the region.

Hemophilia drugs market: Competitive landscape and key vendors

The global hemophilia drugs market highly consolidated with key players including Baxalta, Bayer, CSL Behring, Novo Nordisk, Biogen, and Pfizer, which together account for the majority of market shares. The vendors are focusing on opportunities in emerging markets such as China and India to increase their market share.

 Some hemophilia drug companies are

• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer

Hemophilia drugs market segmentation by type of disease 

• Hemophilia A
• Inhibitors
• Hemophilia B
• Von Willebrand disease

During 2015, the Hemophilia A segment dominated the market and is expected to lead the market during the forecast period. Hemophilia A is more prevalent than hemophilia B and Von Willebrand disease. The development of novel drugs with prolonged action and the increased adoption of prophylactic treatment among individuals will boost this market segment’s growth in the future. The on-demand hemophilia A prophylactics are expected to witness greater acceptance in the emerging countries.

Hemophilia drugs market by type of therapy

• Recombinant therapies
• Plasma-derived therapies

According to the industry research analysts, the recombinant therapies segment accounted for most of the market revenue shares and will continue to lead the market over the coming years. The growth of this segment is attributed to the increasing demand for prophylaxis therapies in developed countries and shift in preference from plasma-derived therapies to recombinant products in the emerging economies. Moreover, the entry of long-acting recombinant products such as ALPROLIX by Biogen, Advate by Baxter, among others will contribute to this segment’s growth over the coming years.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global hemophilia drugs market?
• What are the key market trends impacting the growth of the global hemophilia drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global hemophilia drugs market?
• What are the market opportunities and threats faced by the vendors in the global hemophilia drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global hemophilia drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Hemophilia B Market 2015-2019 - Industry Analysis
• Global Hemophilia A Drugs Market 2015-2019
• Global Alpha-1 Antitrypsin Drugs Market 2016-2020
• Global Blood Coagulation Analyzer Market 2016-2020